Re-Examining Infectious Causes of Alzheimer’s Disease

References

1. Henderson TA. The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. CNS Spectr. 2012; 17(4):176-206.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119-22. 
3. Dementia: a public health priority. World Health Organization. 2012. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed March 26, 2016.
4. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37. 
5. Toyn JH, Ahlijanian MK. Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β. Alzheimers Res Ther. 2014;6(2):14.
6. Stefaniak J, O’Brien J. Imaging of neuroinflammation in dementia: a review. J Neurol Neurosurg Psychiatry. 2016;87(1):21-8.
7. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2(1):a006346.
8. Wozniak MA, Mee AP, Professor Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J Pathol. 2009; 217(1):131-8.
9. Kumar D, Choi S, Washicosky K, et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimers disease. Sci Transl Med. 2016;8(340):340ra72-340ra72. doi:10.1126/scitranslmed.aaf1059.
10. Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer’s Disease. J Alzheimers Dis. 2016;51(4):979-84.
11. Saldanha J, Sutton RN, Gannicliffe A, Farragher B, Professor Itzhaki RF. Detection of HSV1 DNA by in situ hybridisation in human brain after immunosuppression. J Neurol Neurosurg Psychiatr. 1986;49(6):613-9.
12. Jamieson GA, Maitland NJ, Wilcock GK, Craske J, Professor Itzhaki RF. Latent herpes simplex virus type 1 in normal and Alzheimer’s disease brains. J Med Virol. 1991;33(4):224-7.
13. Jamieson GA, Maitland NJ, Wilcock GK, Yates CM, Itzhaki RF. Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J Pathol. 1992;167(4):365-8.
14. Letenneur L, Pérès K, Fleury H, et al. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer’s disease: a population-based cohort study. PLoS ONE. 2008;3(11):e3637.
15. Lövheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F. Herpes simplex infection and the risk of Alzheimer’s disease: A nested case-control study. Alzheimers Dement. 2015;11(6):587-92.
16. Nimgaonkar VL, Yolken RH, Wang T, et al. Temporal Cognitive Decline Associated With Exposure to Infectious Agents in a Population-based, Aging Cohort. Alzheimer Dis Assoc Disord. 2015; [Epub ahead of print]
17. Mancuso R, Baglio F, Cabinio M, et al. Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in Alzheimer’s disease. J Alzheimers Dis. 2014;38(4):741-5.
18. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186 Suppl 1:S3-28.
19. Steel AJ, Eslick GD. Herpes Viruses Increase the Risk of Alzheimer’s Disease: A Meta-Analysis. J Alzheimers Dis. 2015;47(2):351-64.
20. Itzhaki RF, Dobson CB, Shipley SJ, Wozniak MA. The role of viruses and of APOE in dementia. Ann N Y Acad Sci. 2004;1019:15-8.
21. Burgos JS, Ramirez C, Sastre I, Alfaro JM, Valdivieso F. Herpes simplex virus type 1 infection via the bloodstream with apolipoprotein E dependence in the gonads is influenced by gender. J Virol. 2005;79(3):1605-12.
22. Carter CJ. Interactions between the products of the Herpes simplex genome and Alzheimer’s disease susceptibility genes: relevance to pathological-signalling cascades. Neurochem Int. 2008;52(6):920-34.
23. Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett. 2007;429(2-3):95-100.
24. Shipley SJ, Parkin ET, Itzhaki RF, Dobson CB. Herpes simplex virus interferes with amyloid precursor protein processing. BMC Microbiol. 2005;5:48.
25. De Chiara G, Marcocci ME, Civitelli L, et al. APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells. PLoS ONE. 2010;5(11):e13989.
26. Wozniak MA, Frost AL, Itzhaki RF. Alzheimer’s disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis. 2009;16(2):341-50.
27. Wozniak MA, Frost AL, Preston CM, Itzhaki RF. Antivirals reduce the formation of key Alzheimer’s disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS ONE. 2011;6(10):e25152.
28. Barry Marshall (editor), Helicobacter Pioneers. Firsthand accounts from the scientists who discovered helicobacters, 1892-1982, Blackwell Science Asia Pty Ltd. Victoria, AU, 2002.
29. Two win Nobel Prize for discovering bacterium tied to stomach ailments. New York Times. October 10, 2005. http://www.nytimes.com/2005/10/04/science/two-win-nobel-prize-for-discovering-bacterium-tied-to-stomach-ailments.html?_r=0. Accessed March 26, 2016.
30. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet. 1997;349(9047):241-4.
31. Leng J, Goldstein DR. Impact of aging on viral infections. Microbes Infect. 2010;12(14-15):1120-4.
32. Rymkiewicz PD, Heng YX, Vasudev A, Larbi A. The immune system in the aging human. Immunol Res. 2012;53(1-3):235-50.
33. Henderson TA, Woolsey TA, Jacquin MF. Infraorbital nerve blockade from birth does not disrupt central trigeminal pattern formation in the rat. Brain Res Dev Brain Res. 1992;66(1):146-52.
34. Lin WR, Jennings R, Smith TL, Wozniak MA, Itzhaki RF. Vaccination prevents latent HSV-1 infection of mouse brain. Neurobiol Aging. 2001;22(5):699-703.
35. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J Infect Dis. 2002;186 Suppl 1:S40-6.
36. Henderson TA. Valacyclovir treatment of chronic fatigue in adolescents. Adv Mind Body Med. 2014; (1):4-14.